Cure Today: Copper IUD Use Associated with Decreased Cervical Cancer Risk Compared Hormonal Intrauterine System Copper IUD Use Associated with Decreased Cervical Cancer Risk Compared Hormonal Intrauterine System Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer.

Understanding the Context

Breast ... The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ... VentureBeat: Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System. Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.

Key Insights

Nasdaq: Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S. Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S. Monthly Prescribing Reference: Breast Cancer Risk Elevated With Levonorgestrel-Releasing Intrauterine System Use Nasdaq: FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any ... FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any ... Low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg and 19.5 mg is associated with a significantly lower risk of first-time depression vs high dose LNG-IUS 52 mg.

Final Thoughts

Overall, 46,565 ... About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...